

Research Article Open Access

# Quality of Life among Injection Drug Users Living with or without HIV/AIDS in Taiwan: A Case Control Group Design

Tony Szu-Hsien Lee¹, Cheng-Shi Shiu², Yung-Change Tuan³, Wei-Hsin Wu⁴, Chun-Wei Huang⁵, Muh-Yong Yen⁶, Chun-Hsiu Lin¹, Ling-Chun Shen¹ and Chao-Kuang Lin⁻\*

- <sup>1</sup>Department of Health Promotion and Health Education, National Taiwan Normal University, Taiwan
- <sup>2</sup>School of Social Service Administration & Department of Health Studies, University of Chicago, Chicago, IL, USA
- <sup>3</sup>Taipei County Hospitals and Taiwan Medical University, Taiwan
- <sup>4</sup>Department of Psychiatry, Keelung Hospital, Department of Health, Taiwan
- <sup>5</sup>Department of Psychiatry, Lotung Poh-Ai Hospital, Taiwan
- <sup>6</sup>Department of Infection, Taipei City Hospital, Branch for Disease Control and Prevention, Taiwan
- <sup>7</sup>Education Center for Humanities and Social Sciences National Yang-Ming University, Taiwan

### **Abstract**

**Background**: For most HIV/AIDS patients who adhere to their medication regimens, Highly Active Antiretroviral Therapy (HAART) effectively controls viral load, reduces the incidence of AIDS diagnoses, and lowers HIV-associated mortality. Despite strong evidence that HAART effectively increases survival in people living with HIV/AIDS, HIV-infected individuals not only need to endure the physiological changes that occur during therapy, but they may also face social and psychological problems. However, few research studies have paid attention to the quality of life of injection drug users (IDUs) living with HIV. This paper examines quality of life among IDUs living with HIV/AIDS relative to IDUs without HIV/AIDS.

**Methods:** A total of 71 HIV-infected IDUs from 4 methadone clinics in northern Taiwan completed a structured questionnaire that included demographics and the World Health Organization Quality of Life Scale brief version (WHOQOL-BREF). Another 71 HIV-negative IDUs were randomly sampled from 528 available methadone patients at the same 4 clinics as the control group. Scores from the WHOQOL-BREF were compared between HIV-positive and HIV-negative IDUs.

**Results:** Results from multivariate multiple linear regression indicated that after controlling for all other demography and clinical factors, average scores in these four domains of WHOQOL-BREF were significantly higher among HIV-negative patients compared with those in HIV-positive patients. The greatest group difference appeared in the social relations domain, followed by the psychological domain and then the environmental domain, with the least difference found in the physical domain.

**Conclusion:** The findings suggest that social relations and psychological issues are of great concerns for IDUs, especially HIV-positive patients. This indicates that understanding the impact of HIV infection on the quality of life particularly in the psychological and social relations realms is an important topic of future research.

Keywords: HARRT; HIV/AIDS; Injection drug users; Quality of life

### Introduction

Drug injection and related human immunodeficiency virus (HIV) infection pose great challenges to health professionals worldwide. In Taiwan, the number of people using heroin increased during the years 2003 to 2009, and the incidence of contracting the human immunodeficiency virus (HIV) and/or the hepatitis C virus (HCV) increased tenfold during the same time period [1]. Specifically, from 2003 to 2005 newly reported HIV-positive cases increased from 860 to 3,381, and the percentage attributed to injection drug users (IDUs) markedly increased from 2.1% to 72.4% [2,3]. At the end of 2012, the proportion of HIV cases related to Taiwanese IDUs was 27.58% of 24,239 HIV cases [3]. HIV prevalence was estimated to be between 12.3% and 25.5% among IDUs, compared with 0.08% among the general population [2-4].

For most patients who adhere to their medication regimens, HAART effectively controls viral load, reduces the incidence of AIDS diagnoses, and lowers HIV-associated mortality [5,6]. HAART was introduced into Taiwan in April 1997 and was freely offered to all identified HIV-positive citizens through the National Health Insurance system [7], resulting in a dramatic decline in mortality in HIV patients from 64% prior to the introduction of HAART to 8.9% in 2005 [8]. A Taiwan study [9] conducted a survival analysis of 2,633 HIV-positive Taiwan

patients without AIDS and concluded that the estimated lifespan was 21.5 years after diagnosis. Another study [10] from the Danish HIV Cohort Study found that newly diagnosed young persons with HIV (25 years old) demonstrated a marked extension of average life expectancy (ALE) following the introduction of HAART. In this study, ALE increased from about 8 years in 1995-1996 to 23 years in 1997-1999. By 2000-2005, ALE had increased to 33 years, which was three times longer than that of HIV-positive individuals not receiving such therapy and equal to ALE of young persons with diabetes. Therefore, it is well established that early treatment and proper care for persons with HIV/AIDS can extend their ALE.

\*Corresponding author: Chao-Kuang Lin, Education Center for Humanities and Social Sciences National Yang-Ming University, No 155 Sec 2 Linong Street, Taipei, 112 Taiwan, Tel: +886 2 2825-074; Fax:+886 2 2822-8108; E-mail: henrymay@ms22.hinet.net

Received February 18, 2013; Accepted March 22, 2013; Published March 27, 2013

Citation: Lee TSH, Shiu CS, Tuan YC, Wu WH, Huang CW, et al. (2013) Quality of Life among Injection Drug Users Living with or without HIV/AIDS in Taiwan: A Case Control Group Design. J AIDS Clin Res 4: 199. doi:10.4172/2155-6113.1000199

 $\textbf{Copyright:} @ 2013 \ Lee \ TSH, et \ al. \ This \ is \ an open-access \ article \ distributed \ under the terms of the Creative Commons \ Attribution \ License, \ which permits \ unrestricted \ use, \ distribution, \ and \ reproduction \ in \ any \ medium, \ provided \ the \ original \ author \ and \ source \ are \ credited.$ 

Despite strong evidence that HAART effectively increases survival in people living with HIV/AIDS, consequently increasing the cumulative number of persons living with HIV/AIDS, these HIV-positive individuals not only need to endure the physiological changes that occur during therapy, but studies found that they also face social stigma [11,12] and psychological problems [13-16], resulting in depression and suicide. For example, a study [17] provided evidence that from 1994 to 2002, the number of people with HIV/AIDS committing suicide increased by more than three times in Taiwan, from 1.5% in 1994 to 1996 to 4.8% in 2000 to 2002. In other words, although ALE of individuals living with HIV/AIDS has increased as a result of HAART, their suicide rate has also increased. Previous studies have documented the same phenomenon that the number of HIV-positive persons dying from HIV-related diseases has decreased, whereas deaths from suicide-related causes have increased [18-21].

Quality of life is frequently used in general medicine and has become an important indicator for estimating the burden of HIV, but this analysis is not often applied in studying HIV-positive IDUs. Drug injection is associated with HIV infection and multiple negative consequences in a broad range of areas of functioning including physical or psychological problems, personal safety, social relations, roles and obligations, and work [22]. Therefore, although HAART and methadone can alleviate the physical symptoms of HIV/AIDS [13] and opioid dependence [23], respectively, QoL, as a continuous process, can remain a critical issue for IDUs with HIV. Although studies have suggested that dual diagnosis of dependence and HIV is harmful to health-related QoL [16,24], there is a lack of investigation into the impact on QoL for HIV-infected IDUs [25,26]. Moreover, the extension to life resulting from HAART enhances the importance of the maintenance and optimization of QoL during this extended lifespan.

Compared with other chronic disease patients, health of HIV-positive IDUs is threatened by the extensive complications and comorbidity of HIV and drug addiction across the therapy process. Some studies have documented that individuals with either HIV infection or dependence per se had significantly lower QoL than patients with other chronic medical conditions [27,28], but no study has been conducted to examine the difference between HIV-positive and HIV-negative IDUs [24]. This study compares the QoL scores in IDUs with and without HIV. We hypothesize that IDUs with HIV are more likely to have lower QoL compared with those without HIV, especially in the psychological and social relation domains.

### Methods

### **Participants**

A case-control sample of HIV-positive and HIV-negative IDUs was selected from a study evaluating the impact of methadone treatment on heroin lapse, risk behaviours, and QoL, from four hospitals in northern Taiwan. The criteria for IDU inclusion in the present study were as follows: 18 years of age or older, literate, morphine positive, and self-reported heroin injection in the past six months. This research was approved by the Institutional Review Board of Human Subject Protection at the Taipei Medical University (approval number P960205). After an explanation of the purpose of the research to potential IDU participants, participants signed consent forms, received HIV testing, and completed a self-administered questionnaire. A total of 599 available methadone treatment patients were invited to participate in this study. All data were collected between August and November 2008.

### Measures

A semistructured questionnaire asked for background information and quality of life. The solicited demographic information included age, gender, age at first heroin use, education, marital status, and employment status. Because a minimum of nine years education is compulsory in Taiwan, education was categorized as less than nine years and at least nine years in school. Marital status was categorized as married, single, and other (divorced/widowed). Employment status was categorized as jobless, seasonal labor, and full time. After we obtained patient consent, records for the clinical characteristics examined in the study were retrieved from patient files in the hospital's computer systems. The data included confirmed HIV status, HCV status, morphine detected by urine tests, and methadone dosage at intake.

Quality of life: For this study, quality of life was defined as "an individual's perception of their position in life, in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns" [29]. This study used the World Health Organization Quality of Life Scale brief version (WHOQOL-BREF), which was developed to measure overall QoL and ordinary health states [29-31]. The WHOQOL-BREF includes 4 domains (physical, psychological, social, and environmental) and has a total of 26 questions: 7 items for the physical domain (energy and fatigue; pain and discomfort; sleep and rest; mobility; activities of daily living; dependence on medicinal substances; work capacity), 6 items for the psychological domain (body image and appearance; negative feelings; positive feelings; self-esteem; thinking, learning, memory, and concentration; religion/spirituality/personal beliefs), 3 items for the social domain (personal relationships; social support; sexual activity), and 8 items for the environmental domain (financial resources; freedom, physical safety, and security; accessibility and quality of health and social care; home environment; opportunities for acquiring new information and skills; participation in and opportunities for recreation/leisure; pollution/noise/traffic/climate; transport), as well as 2 additional questions on overall quality of life and general health.

**Scoring:** The WHOQOL-BREF questionnaire uses a five-point Likert scale and is coded from 1–5 points. Four types of scale descriptors (capacity, frequency, intensity, and evaluation) for Taiwan were specially selected. Participants responded to questions according to their experience in the previous two weeks. Reverse items (items 3, 4 and 26) were scored reversely. After adding up the scores for items in corresponding domains, the original domain scores were transformed to a scale of 0-100. Higher scores for a particular domain indicated better quality of life in that domain [31].

Reliability and validity of WHOQOL-BREF: The WHOQOL-Taiwan Group [31] collected data from 848 patients and 212 healthy controls from 17 hospitals in Taiwan for assessment of the scale's validity and reliability and concluded that the coefficients indicate that measures of the WHOQOL-BREF have adequate reliability and validity. The internal consistency (Cronbach's a) coefficients in this study for physical, psychological, social relations, and environmental domains were 0.80, 0.77, 0.7, and 0.82, respectively. Results of confirmatory factor analysis found that items from the four domains all had factor loadings greater than 0.30. The correlations between the four domains were 0.62 (physical and psychological), 0.65 (physical and social relations), 0.72 (physical and environmental), 0.76 (psychological and social relations and environmental).

9 (7.99) 3 6 (7.85) 1 1 (16.25) 5 1 (15.59) 4 1 (17.02) 5 1 (15.08) 5	HIV + Mean (SD) 39.61 (7.82) 13.85 (6.65) 58.22 (17.57) 45.27 (15.91) 50.18 (18.61) 54.89 (16.15) Percentage  89.39 10.61 30.77 69.23 15.63 64.06	HIV - Mean (SD) 40.73 (8.16) 12.85 (8.94) 66.20 (13.96) 60.04 (11.43) 67.43 (9.79) 65.45 (12.05) Percentage  88.73 11.27  22.86 77.14	P value  0.4119  0.4813  0.0040  0.0000  0.0000  0.901  0.299
9 (7.99) 3 6 (7.85) 1 1 (16.25) 5 6 (15.59) 4 6 (17.02) 5 7 (15.08) 5 9.05 0.95 0.95 0.95	39.61 (7.82) 13.85 (6.65) 58.22 (17.57) 45.27 (15.91) 50.18 (18.61) 54.89 (16.15) Percentage 89.39 10.61 30.77 69.23	40.73 (8.16) 12.85 (8.94) 66.20 (13.96) 60.04 (11.43) 67.43 (9.79) 65.45 (12.05) Percentage 88.73 11.27 22.86 77.14	0.4813 0.0040 0.0000 0.0000 0.0000 0.901
6 (7.85) 1  6 (16.25) 5  6 (15.59) 4  6 (17.02) 5  7 (15.08) 5  6 entage      9.05  0.95  6.67  3.33	13.85 (6.65) 58.22 (17.57) 45.27 (15.91) 50.18 (18.61) 54.89 (16.15) Percentage 89.39 10.61 30.77 69.23	12.85 (8.94) 66.20 (13.96) 60.04 (11.43) 67.43 (9.79) 65.45 (12.05) Percentage  88.73 11.27  22.86 77.14	0.4813 0.0040 0.0000 0.0000 0.0000 0.901
(16.25) 5 (15.59) 4 (17.02) 5 (15.08) 5 (15.08) 5 entage [9.05] 0.95 0.95	58.22 (17.57) 45.27 (15.91) 50.18 (18.61) 54.89 (16.15) Percentage 89.39 10.61 30.77 69.23	66.20 (13.96) 60.04 (11.43) 67.43 (9.79) 65.45 (12.05) Percentage 88.73 11.27 22.86 77.14	0.0040 0.0000 0.0000 0.0000 0.901
(15.59) 4 (17.02) 5 (15.08) 5 (15.08) 5 entage F	45.27 (15.91) 50.18 (18.61) 54.89 (16.15) Percentage 89.39 10.61 30.77 69.23	60.04 (11.43) 67.43 (9.79) 65.45 (12.05) Percentage 88.73 11.27 22.86 77.14	0.0000 0.0000 0.0000 0.901
(15.59) 4 (17.02) 5 (15.08) 5 (15.08) 5 entage F	45.27 (15.91) 50.18 (18.61) 54.89 (16.15) Percentage 89.39 10.61 30.77 69.23	60.04 (11.43) 67.43 (9.79) 65.45 (12.05) Percentage 88.73 11.27 22.86 77.14	0.0000 0.0000 0.0000 0.901
(17.02) 5 (15.08) 5 (15.08) 5 (15.08) 5 (15.08) 5 (15.08) 6 (15.08	50.18 (18.61) 54.89 (16.15) Percentage 89.39 10.61 30.77 69.23	67.43 (9.79) 65.45 (12.05) Percentage 88.73 11.27 22.86 77.14	0.0000 0.0000 0.901
9.05 0.95 0.95 3.33	54.89 (16.15) Percentage  89.39 10.61  30.77 69.23	65.45 (12.05) Percentage  88.73 11.27  22.86 77.14  38.1	0.0000
9.05 0.95 6.67 3.33	89.39 10.61 30.77 69.23	88.73 11.27 22.86 77.14	0.901
9.05 0.95 6.67 3.33	89.39 10.61 30.77 69.23	88.73 11.27 22.86 77.14	0.299
0.95 6.67 3.33	30.77 69.23	22.86 77.14	0.299
0.95 6.67 3.33	30.77 69.23	22.86 77.14	0.299
6.67 3.33	30.77 69.23	22.86 77.14 38.1	
3.33	69.23	77.14	
3.33	69.23	77.14	
6.77	15.63	38.1	0.011
			0.011
			0.011
2.76	64.06	44.0=	
		41.27	
0.47	20.31	20.63	
0.00	55.74	44.44	0.049
0.48	14.75	6.35	
9.52	29.51	49.21	
		-	
4.37	46.48	42.25	0.67
2.25	43.66	40.84	
0.86	7.04 12.68		
5.52	2.82	4.23	
	-		
62	0	8.7	0.029
-	-	-	0.020
	100	31.3	
J.30			
4.85	47.69	22.39	0.002
3	3.52 1.62 5.38	3.52 2.82 4.62 0	3.52 2.82 4.23 4.62 0 8.7 5.38 100 91.3

**Table 1**: Sample Characteristics and Bivariate Analysis between HIV Status and Independent and Outcome Variables.

### Statistical analysis

Descriptive statistics were used to identify the characteristics of the entire sample and the two HIV groups. Bivariate analysis was conducted to evaluate differences between the two groups regarding the demography and clinical factors, as well as the four domains of quality of life. Chi-square tests, Fisher exact tests, and two independent sample t-tests were applied when appropriate. Continuous variables in this study met the normality assumption. To better estimate the differences among the four domains of the quality of life between the two groups, multivariate multiple linear regression was performed to compare the two groups on the four domains simultaneously while controlling for all the other demography and clinical factors. This was possible because the four domains were subscales of the WHOQOL-BREF and moderately correlated with each other. Finally, because missing values were substantial (20%), we checked potential missing mechanisms

and decided to conduct multiple imputations to handle missing data. However, as the estimations from the imputed data were very close to those from the complete-case data, we then adapted the latter. All the statistical analysis was conducted in STATA 12 [32].

## Results

### Participants' characteristics

Of available patients, 71 IDUs were tested HIV positive. Participants all agreed to participate in this study and were not receiving HAART at the time of data collection. Another 71 control cases of HIV-negative IDUs were randomly sampled from the remaining patients. As shown in Table 1, for the entire sample, the participants were on average 40.19 years old (SD = 7.99) and had used heroin for 13.36 years (SD = 7.85). About 11% of the entire sample was female; about half of the sample were still single and only a quarter were married; 73.33% had completed high school education; about 40% worked full time while another 50% were unemployed; about 95% were co-infected with hepatitis C; and finally, about two thirds of the sample had detectable morphine levels in their urine during the treatment intake. In bivariate analysis as shown in Table 1, age, gender, years using heroin, study sites, and education levels did not differ between the two groups. However, compared with those without HIV, those IDUs with HIV were less likely to be married, less likely to be working full time, less likely to have detectable morphine levels, but more likely to have co-infection with hepatitis C. Finally, HIV-positive participants ranked significantly lower than HIVnegative participants on all four domains of the quality of life.

## Using multivariate multiple linear regression to examine the mean scores of QoL domains between HIV-positive and HIV-negative IDUs

When controlling for all other demography and clinical factors, HIV status was still significantly related to all four domains of quality of life (Wilks's lambda, Lawley-Hotelling's trace, Pillai's trace, and Roy's largest root all reached significant levels at 0.001 levels, not shown in the table). The comparisons among groups in the domains of quality of life are summarized in Table 2. HIV-positive IDUs scored on average 7.631 (95% CI 0.669, 14.592), 12.270 (95% CI 6.156, 17.257), 17.997 (95% CI 11.752, 24.243), and 9.700 (95% CI 3.646, 15.747) units lower than their HIV-negative counterparts on the physiological, psychological, social relations, and environmental domains of QoL, respectively. The greatest group difference appeared in the social domain, followed by psychological, then the environmental domain, with the least difference in the physical domain.

	Observed data (N = 111)				
	Coef.1	Std. Err.	P>t	[95% Conf. Interval]	
Physical Domain					
HIV + (vs. HIV - )	-7.631	3.505	0.032	-14.5920.669	
Psychological Domain					
HIV + (vs. HIV - )	-12.270	2.794	0.000	-17.257 — -6.156	
Social Relations Domain					
HIV + (vs. HIV - )	-17.997	3.144	0.000	-24.243 – -11.752	
Environmental Domain					
HIV + (vs. HIV - )	-9.700	3.046	0.000	-15.747 — -3.646	

<sup>&</sup>lt;sup>1</sup> The coefficients were all adjusted further for age, gender, marital status, education, years of heroin use, study sites, and two biomarkers. Residuals met the normality assumption

**Table 2:** Average Group Differences in Four Domains of Quality of Life between HIV-positive and HIV-negative Methadone Patients Using Multiple Multivariate Linear Regression.

### Discussion

Our study findings showed that HIV-positive IDUs had lower QoL than IDUs without HIV. Though previous studies have documented that HAART treatment increases the ALE and accessibility of people living with HIV/AIDS [9,10], our study findings bring attention to the concept that HIV/AIDS has become for many a chronic disease, but few studies have attempted to understand the QoL and life experiences of HIV-positive IDUs. Furthermore, a few studies [33-35] have suggested that good QoL can lead to better health outcomes in disease sufferers and that health-related QoL can predict survival among individuals living with HIV/AIDS [14].

The results pertaining to employment and marital status, and the magnitudes of the differences of QoL scores among HIV-positive IDUs in the psychological and social domains were consistent with those of another study on QoL in people living with HIV/AIDS following treatment with HAART. Yen et al. [36] found low scores in the psychological and social domains of QoL in people living with HIV/AIDS, who faced a range of problems including depression, deteriorating work function, inconvenience of follow-up visits, lack of social support, and negative stress. The results indicate that regardless of the mode of infection, people living with HIV/AIDS have worse QoL in the domains of psychological health and social relationships. However, a study [37] has suggested that people living with HIV/ AIDS who also use drugs face more severe social stress and isolation. In addition, a study has found that people living with HIV/AIDS who are also drug users have lower QoL than those who do not use drugs [16]. This is because IDUs living with HIV/AIDS not only face potential harms from HIV but also must deal with the problem of drug addiction and the social stigma associated with both conditions.

The lower scores observed in the psychological and social relations domains indicate that the assistance and care provided in these two domains can be enhanced. Although many case managers in Taiwan hospitals may provide brief counselling and education services to HIV-positive IDUs, there is a lack of professional and continuous support of this kind. Our findings may indicate that psychological interventions, consultation, and education currently provided to IDUs with HIV/AIDS are probably insufficient in northern Taiwan. Therefore, psychological health should be considered one of the priorities for enhancement of QoL, as well as the physical threat posed by HIV. The lower scores reported by the HIV-positive IDU group for the social relations and psychological domain warrant further study.

In this study, results showed that not only did IDUs with HIV have lower physical QoL scores compared with the IDUs without HIV, but they also had lower scores in the environmental domain. That the score differences were significant but smaller in the physical and environmental domains could be a reflection of the facets measured and the large amount of personnel and resources invested in addiction-related medical services through low-threshold methadone treatment [38].

## Research limitations and conclusions

This study has some limitations. The HIV-positive participants in our sample were not randomly selected from a nationwide pool and may be associated with unspecified selection biases, limiting our ability to generalize conclusions to the larger population of HIV-positive IDUs. It is also noteworthy that our sample consisted of heroin-dependent patients in only four methadone clinics, limiting the extent of generalizability. Moreover, we did not have data on participants' duration of HIV infection, which can affect QoL. Additionally, there

is potential for response bias to occur given that the questionnaire was self-administered. Despite these research limitations, there are a limited number of studies on QoL among IDUs with HIV from a chronic disease perspective, and this study attempts to makes an important contribution to the field.

In conclusion, IDUs with HIV have lower scores for every aspects of QoL and, in particular, much lower scores for the psychological and social relations domains compared with IDUs without HIV in Taiwan. These findings indicate that IDUs with HIV may benefit from increased counselling, health education and intervention aimed at their mental health and social relations, in order to enhance their QoL.

### Acknowledgements

This research was supported by the National Science Council, Taiwan, R.O.C. (grant number NSC96-2314-B-003-003) and the National Bureau of Controlled Drugs, Department of Health, Taiwan, R.O.C. (grant number DOH97-NNB-1044). We are indebted to the study participants for their participation. We are also grateful to the methadone treatment staff for their assistance.

#### References

- 1. http://www.cdc.gov.tw/english/index.aspx
- Lee TS, Shen HC, Wu WH, Huang CW, Yen MY, et al. (2011) Clinical characteristics and risk behavior as a function of HIV status among heroin users enrolled in methadone treatment in northern Taiwan. Subst Abuse Treat Prev Policy 6: 6.
- 3. http://www.cdc.gov.tw/english/index.aspx
- Chu FY, Chiang SC, Su FH, Chang YY, Cheng SH (2009) Prevalence of human immunodeficiency virus and its association with hepatitis B, C, and D virus infections among incarcerated male substance abusers in Taiwan. J Med Virol 81: 973-978.
- Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, et al. (2003) Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362: 1267-1274.
- Sabin CA, Smith CJ, Youle M, Lampe FC, Bell DR, et al. (2006) Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 20: 67-71.
- Fang CT, Hsu HM, Twu SJ, Chen MY, Chang YY, et al. (2004) Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 190: 879-885.
- Yang CH, Yang SY, Shen MH, Kuo HS (2008) The changing epidemiology of prevalent diagnosed HIV infections in Taiwan, 1984-2005. Int J Drug Policy 19: 317-323
- Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, et al. (2007) Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy, QJM 100: 97-105.
- Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, et al. (2007) Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146: 87-95.
- Holzemer WL, Human S, Arudo J, Rosa ME, Hamilton MJ, et al. (2009) Exploring HIV stigma and quality of life for persons living with HIV infection. J Assoc Nurses AIDS Care 20: 161-168.
- Greeff M, Uys LR, Wantland D, Makoae L, Chirwa M, et al. (2010) Perceived HIV stigma and life satisfaction among persons living with HIV infection in five African countries: a longitudinal study. Int J Nurs Stud 47: 475-486.
- Carrieri P, Spire B, Duran S, Katlama C, Peyramond D, et al. (2003) Healthrelated quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 32: 38-47.
- Préau M, Leport C, Salmon-Ceron D, Carrieri P, Portier H, et al. (2004) Healthrelated quality of life and patient-provider relationships in HIV-infected patients during the first 3 years after starting PI-containing antiretroviral treatment. AIDS Care 16: 649-661.
- Préau M, Protopopescu C, Spire B, Sobel A, Dellamonica P, et al. (2007) Health related quality of life among both current and former injection drug users who are HIV-infected. Drug Alcohol Depend 86: 175-182.

- 16. te Vaarwerk MJ, Gaal EA (2001) Psychological distress and quality of life in drug-using and non-drug-using HIV-infected women. Eur J Public Health 11: 109-115.
- 17. Lu TH, Chang HJ, Chen LS, Chu MH, Ou NM, et al. (2006) Changes in causes of death and associated conditions among persons with HIV/AIDS after the introduction of highly active antiretroviral therapy in Taiwan. J Formos Med Assoc 105: 604-609.
- 18. Valdez H, Chowdhry TK, Asaad R, Woolley IJ, Davis T, et al. (2001) Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995--1999. Clin Infect Dis 32: 1487-1493.
- 19. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, et al. (2002) Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 16: 1663-1671.
- 20. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, et al. (2006) Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 41: 194-200.
- 21. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, et al. (2006) Mortality in the highly active antiretroviral therapy era. Changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr 43: 27-34
- 22. Chen CY, Lin KM (2009) Health consequences of illegal drug use. Curr Opin Psvchiatry 22: 287-292
- 23. Ward J, Hall W, Mattick RP (1999) Role of maintenance treatment in opioid dependence. Lancet 353: 221-226.
- 24. Dalgard O, Egeland A, Skaug K, Vilimas K, Steen T (2004) Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 39: 74-80.
- 25. Korthuis PT, Zephyrin LC, Fleishman JA, Saha S, Josephs JS, et al. (2008) Health-related quality of life in HIV-infected patients: the role of substance use. AIDS Patient Care STDS 22: 859-867.
- 26. Litwin AH, Soloway I, Gourevitch MN (2005) Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 40 Suppl 5: S339-345.
- 27. Wachtel T. Piette J. Mor V. Stein M. Fleishman J. Carpenter C (1992) Quality of

- life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study instrument. Ann Intern Med 116: 129-137
- 28. O'Brien S, Mattick RP, White J, Breen C, Kimber J, et al. (2006) Maintenance pharmacotherapy for opioid dependence and SF-36 health status: A comparison with general population norms and other chronic disorders. Addictive Disorders & Their Treatment 5: 155-164.
- 29. [No authors listed] (1998) Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med 28: 551-558.
- Lin MR, Yao GKP, Hwang JS, Wang JD (1999) Scale descriptor selection for Taiwan-version of questionnaire of World Health Organization quality of life. Chinese J Public Health 18: 262-270.
- 31. The WHOQOL-Taiwan Group (2000) Introduction to the development of the WHOQOL-Taiwan Version. Chinese J Public Health 19: 315-324
- 32. StataCorp (2012) STATA 12: Data analysis and statistical software. Bryan/ College Station, TX: StataCorp LP.
- 33. Chandra PS, Deepthivarma S, Jairam KR, Thomas T (2003) Relationship of psychological morbidity and quality of life to illness-related disclosure among HIV-infected persons. J Psychosom Res 54: 199-203.
- 34. Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Kyriakides TC, et al. (2009) Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. J Acquir Immune Defic Syndr 50: 27-36.
- 35. de Boer-van der Kolk IM, Sprangers MA, Prins JM, Smit C, de Wolf F, et al. (2010) Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort. Clin Infect Dis 50: 255-263.
- 36. Yen CF, Tsai JJ, Lu PL, Chen YH, Chen TC, et al. (2004) Quality of life and its correlates in HIV/AIDS male outpatients receiving highly active antiretroviral therapy in Taiwan. Psychiatry Clin Neurosci 58: 501-506.
- 37. Klee H (1995) Drug misuse and suicide: assessing the impact of HIV. AIDS Care 7 Suppl 2: S145-155.
- 38. Yen YF, Yen MY, Su LW, Li LH, Chuang P, et al. (2012) Prevalences and associated risk factors of HCV/HIV co-infection and HCV mono-infection among injecting drug users in a methadone maintenance treatment program in Taipei, Taiwan. BMC Public Health 12: 1066.

## Submit your next manuscript and get advantages of OMICS Group submissions

### Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

### Special features:

- 250 Open Access Journals
- 20.000 editorial team 21 days rapid review process
- Quality and quick editorial, review and publication processing Indexing at PubMed (partial), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: http://www.omicsonline.org/submission

Citation: Lee TSH, Shiu CS, Tuan YC, Wu WH, Huang CW, et al. (2013) Quality of Life among Injection Drug Users Living with or without HIV/AIDS in Taiwan: A Case Control Group Design. J AIDS Clin Res 4: 199. doi:10.4172/2155-6113.1000199